title: Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a leukemia intergroup study.
abstract: In an effort to determine if cell cycle active agents are augmented when given after non-cell cycle active agents, 104 patients with either multiply relapsed or refractory acute nonlymphocytic leukemia or blast crisis of chronic myelogenous leukemia were treated with mitoxantrone. Patients whose bone marrow did not show significant cytoreduction received 5-azacytidine. Twenty-seven of the 93 evaluable patients (23%) with ANLL achieved a complete remission. A total of 28% of patients receiving mitoxantrone alone achieved remission compared to 15% for those receiving mitoxantrone and 5-azacytidine. Relapsed patients had a higher CR rate (36%) than refractory patients (15%). Nausea, vomiting, and stomatitis were common but rarely severe. The median duration of remission was 3.7 months and patients with abnormal karyotypes had longer remission durations than those with normal karyotypes. In this patient population, there was no evidence that 5-azacytidine given after mitoxantrone increased the complete remission rate.
authors.affiliation: Cooper University Medical Center, Camden, New Jersey 08103.
authors.forename: J
authors.initials: J
authors.lastname: Goldberg
authors.forename: J
authors.initials: J
authors.lastname: Gryn
authors.forename: A
authors.initials: A
authors.lastname: Raza
authors.forename: J
authors.initials: J
authors.lastname: Bennett
authors.forename: G
authors.initials: G
authors.lastname: Browman
authors.forename: J
authors.initials: J
authors.lastname: Bryant
authors.forename: H
authors.initials: H
authors.lastname: Grunwald
authors.forename: R
authors.initials: R
authors.lastname: Larson
authors.forename: R
authors.initials: R
authors.lastname: Vogler
authors.forename: H
authors.initials: H
authors.lastname: Preisler
mesh_terms: D000328:Adult; D001374:Azacitidine / Q000009:adverse effects / Q000627:therapeutic use*; D001706:Biopsy; D001752:Blast Crisis; D001853:Bone Marrow / Q000473:pathology; D002453:Cell Cycle; D004273:DNA, Neoplasm / Q000235:genetics; D005260:Female; D006801:Humans; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000009:adverse effects / Q000627:therapeutic use*; D017063:Outcome Assessment, Health Care; D012008:Recurrence
chemical_list: D004273:DNA, Neoplasm; D008942:Mitoxantrone; D001374:Azacitidine